Cite

    Ehret, F., Hansch, A., Meinhardt, J., Hain, E. G., Misch, M., Onken, J., Roohani, S., Koch, A., Schweizer, L., Radke, J., & Kaul, D. (2023). loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH‐mutant and 1p/19q‐codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report. Neuropathology & applied neurobiology, 49(1), n/a. http://access.bl.uk/ark:/81055/vdc_100179851040.0x000049